A dosage form coating composition is disclosed. The composition includes an alginate, a pectin, a plasticizer, and optionally an emulsifying agent. The alginate is present in an amount by weight of at least 40.0% and at most 80.0% and the pectin is present in an amount by weight of at least 16.0% and at most 40.0%—and/or—the alginate and the pectin are present in a weight ratio of at least 1:1 and at most 5:1. The dosage form coating composition, when applied to a dosage form to a 3% to 5% weight gain, provides a coated dosage form having an enteric coating. The coated dosage form has at least two sequentially observed properties exhibiting enteric coating behavior.

A dosage form coating composition is disclosed. The composition includes an alginate, a pectin, a plasticizer, and optionally an emulsifying agent. The alginate is present in an amount by weight of at least 40.0% and at most 80.0% and the pectin is present in an amount by weight of at least 16.0% and at most 40.0%—and/or—the alginate and the pectin are present in a weight ratio of at least 1:1 and at most 5:1. The dosage form coating composition, when applied to a dosage form to a 3% to 5% weight gain, provides a coated dosage form having an enteric coating. The coated dosage form has at least two sequentially observed properties exhibiting enteric coating behavior.

A nutraceutical composition including one or more sources of fiber, glutamine, one or more probiotics, one or more sources of omega-3, and one or more antioxidants, for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota. Also, a method for preventing and/or treating dysbiosis including a step of administering the nutraceutical composition to a patient in need thereof. Further, a three-part kit for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota.

A nutraceutical composition including one or more sources of fiber, glutamine, one or more probiotics, one or more sources of omega-3, and one or more antioxidants, for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota. Also, a method for preventing and/or treating dysbiosis including a step of administering the nutraceutical composition to a patient in need thereof. Further, a three-part kit for use in the prevention and/or treatment of dysbiosis of the intestinal microbiota.

A hydrolysate product from a vegetal matrix is disclosed, the process for its preparation, and its uses in human and animal diet. This hydrolysate contains a high percentage of pentosans with a low molecular weight that thus offers highbiodavailability of soluble fibres. This enables the drawbacks to be overcome that are associated with high consumption of wholefood products, at the same time benefiting from the nutritional components contained therein.

A hydrolysate product from a vegetal matrix is disclosed, the process for its preparation, and its uses in human and animal diet. This hydrolysate contains a high percentage of pentosans with a low molecular weight that thus offers highbiodavailability of soluble fibres. This enables the drawbacks to be overcome that are associated with high consumption of wholefood products, at the same time benefiting from the nutritional components contained therein.

The invention relates to a product for use in the therapeutic or prophylactic treatment of infections, said treatment comprising oral administration of the product, wherein the product is selected from a nutritional formulation, a food product, a dietary supplement, a beverage and a pharmaceutical product, said product containing carrot RG-I polysaccharides having the following combination features: a molecular weight in the range 10-300 kDa; a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1.fwdarw.4)-galacturonic-alpha(1.fwdarw.2)-rhamnose residues; the following monosaccharide composition: 20-60 mol. % galacturonic acid residues, wherein the individual galacturonic acids can be methylated and/or acetyl-esterified; 8-50 mol. % rhamnose residues; 0-40 mol. % arabinose residues; 0-40 mol. % galactose residues; molar ratio of galacturonic acid residues to rhamnose residues in the range of 5:1 to 1:1; galacturonic acid residues, rhamnose residues, arabinose residues and galactose residues together constitute at least 85 mol. % of the monosaccharide residues in the carrot RG-I polysaccharides. These carrot RG-I polysaccharides can be produced by partially hydrolysing pectic polysaccharides present in a carrot pectin isolate. The effectiveness of carrot RG-I polysaccharides against infections is substantially improved by enzymatically hydrolysing the RG-I polysaccharides to remove at least part of the homogalacturonan component.

The invention relates to a product for use in the therapeutic or prophylactic treatment of infections, said treatment comprising oral administration of the product, wherein the product is selected from a nutritional formulation, a food product, a dietary supplement, a beverage and a pharmaceutical product, said product containing carrot RG-I polysaccharides having the following combination features: a molecular weight in the range 10-300 kDa; a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1.fwdarw.4)-galacturonic-alpha(1.fwdarw.2)-rhamnose residues; the following monosaccharide composition: 20-60 mol. % galacturonic acid residues, wherein the individual galacturonic acids can be methylated and/or acetyl-esterified; 8-50 mol. % rhamnose residues; 0-40 mol. % arabinose residues; 0-40 mol. % galactose residues; molar ratio of galacturonic acid residues to rhamnose residues in the range of 5:1 to 1:1; galacturonic acid residues, rhamnose residues, arabinose residues and galactose residues together constitute at least 85 mol. % of the monosaccharide residues in the carrot RG-I polysaccharides. These carrot RG-I polysaccharides can be produced by partially hydrolysing pectic polysaccharides present in a carrot pectin isolate. The effectiveness of carrot RG-I polysaccharides against infections is substantially improved by enzymatically hydrolysing the RG-I polysaccharides to remove at least part of the homogalacturonan component.

A composition and a method for improving mood, particularly reducing stress, anxiety and/or depression including administering a composition including at least two prebiotics selected from a source of pectin, a source of beta-glucan, a source of xylooligosaccharide and Ashwagandha. The composition may be in the form of a supplement that is added to a diet (supplements a normal human diet). The composition includes the at least two prebiotics in an amount to increase production of (A) tryptophan or (B) tryptophan and/or at least one of (i) indole, (ii) an indole derivative, (iii) 2,3-pyridinecarboxylic acid (iv) 3-(4-hydroxyphenyl) propionic acid and (v) a short chain fatty acid or (C) any other metabolite (e.g., dopamine, serotonin, GABA) relevant to (eg. benefitting) brain health such as improving mood.

A composition and a method for improving mood, particularly reducing stress, anxiety and/or depression including administering a composition including at least two prebiotics selected from a source of pectin, a source of beta-glucan, a source of xylooligosaccharide and Ashwagandha. The composition may be in the form of a supplement that is added to a diet (supplements a normal human diet). The composition includes the at least two prebiotics in an amount to increase production of (A) tryptophan or (B) tryptophan and/or at least one of (i) indole, (ii) an indole derivative, (iii) 2,3-pyridinecarboxylic acid (iv) 3-(4-hydroxyphenyl) propionic acid and (v) a short chain fatty acid or (C) any other metabolite (e.g., dopamine, serotonin, GABA) relevant to (eg. benefitting) brain health such as improving mood.